Status:
RECRUITING
PRecisiOn Medicine In StrokE: Evolution of Plasma Brain-Derived Tau in Acute Stroke
Lead Sponsor:
Ludwig-Maximilians - University of Munich
Conditions:
Stroke
Stroke, Acute
Eligibility:
All Genders
18+ years
Brief Summary
The investigators recently identified Brain-derived tau (BD-tau) as a sensitive blood-based biomarker for brain injury in acute ischemic stroke: in patients with acute ischemic stroke, plasma BD-tau w...
Detailed Description
Ischemic stroke remains a leading cause of death and long-term disability worldwide,1 despite major advancements in reperfusion therapies.2,3 While neuroimaging modalities have expanded patient eligib...
Eligibility Criteria
Inclusion
- clinical diagnosis of acute ischemic stroke
- presentation within 9 hours of symptom onset
- large- or medium-vessel occlusion (i.e. an occlusion of the ICA, MCA \[segments M1-M4\], ACA \[segments A1-A3\], basilar artery, or PCA \[segments P1 to P3\]) confirmed by CT or MRI angiography
- at least 18 years of age
- written informed consent
Exclusion
- CT or MRI showing intracranial hemorrhage upon admission
- A history of ischemic stroke, subarachnoid hemorrhage, intracerebral hemorrhage, subdural hematoma, epidural hematoma, CNS tumor, meningitis, or encephalitis within the last three months
- severe renal dysfunction (eGFR \< 30ml/min/1.73m2)
- dementia
- pre-stroke disability defined as a premorbid modified Rankin Scale score \> 1
Key Trial Info
Start Date :
March 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06121336
Start Date
March 1 2023
End Date
September 30 2026
Last Update
September 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
LMU University hospital, LMU Munich
Munich, Bavaria, Germany, 81377